We are live on ! Find out more
MED icon

Medifast

124 hedge funds and large institutions have $348M invested in Medifast in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more call options, than puts

Call options by funds: $4.41M | Put options by funds: $2.06M

4.88% more ownership

Funds ownership: 81.17%86.05% (+4.9%)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

0% more funds holding

Funds holding: 124124 (0)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

15% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 46

38% less capital invested

Capital invested by funds: $560M → $348M (-$213M)

Holders
124
Holders Change
Holders Change %
0%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
17
Increased
39
Reduced
46
Closed
16
Calls
$4.41M
Puts
$2.06M
Net Calls
+$2.35M
Net Calls Change
-$1.6M
Name Holding Trade Value Shares
Change
Change in
Stake
VAM
1
Visium Asset Management
New York
$45.3M
BFA
2
BlackRock Fund Advisors
California
$22.8M +$690K +22,152 +3%
EC
3
Engaged Capital
California
$20.5M +$735K +23,609 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$19.8M -$91.6K -2,942 -0.5%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$16.2M -$887K -28,488 -6%
GGPE
6
Golden Gate Private Equity
California
$15.8M
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$15.7M +$233K +7,484 +2%
BIT
8
BlackRock Institutional Trust
California
$12.2M -$713K -22,885 -6%
KCM
9
Kennedy Capital Management
Missouri
$11.7M +$2.5M +80,205 +30%
Renaissance Technologies
10
Renaissance Technologies
New York
$10.3M +$2.23M +71,600 +30%
1WCM
11
12 West Capital Management
New York
$10.3M -$10.2M -327,670 -52%
State Street
12
State Street
Massachusetts
$10.2M -$1.43K -46 -0%
SCM
13
Sterling Capital Management
North Carolina
$7.37M -$1.94M -62,275 -22%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$6.87M +$72.6K +2,330 +1%
OAM
15
Oxford Asset Management
United Kingdom
$6.71M +$3.44M +110,535 +124%
Northern Trust
16
Northern Trust
Illinois
$4.95M -$320K -10,288 -7%
AQR Capital Management
17
AQR Capital Management
Connecticut
$4.86M +$1.78M +57,022 +65%
Millennium Management
18
Millennium Management
New York
$4.47M +$4.15M +133,154 New
RHJA
19
Rice Hall James & Associates
California
$4.23M +$1.26M +40,355 +47%
CS
20
Credit Suisse
Switzerland
$4.07M +$427K +13,724 +13%
CCPM
21
Cooper Creek Partners Management
New York
$3.92M +$323K +10,373 +10%
BNP Paribas Asset Management
22
BNP Paribas Asset Management
France
$3.9M -$1.64M -52,642 -31%
ISL
23
Ingalls & Snyder LLC
New York
$3.46M -$374K -12,010 -10%
PRCP
24
Pacific Ridge Capital Partners
Oregon
$3.23M +$391K +12,560 +15%
AL
25
AJO LP
Pennsylvania
$3.11M +$2.88M +92,600 New

MED Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q4 2014, worth a combined $348M — down 38% from $560M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MED positions and 16 closed out — a net gain of 1 holder — while 39 added to existing stakes and 46 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $4.15M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $221M sold.

  • 124 institutional investors held Medifast (MED) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $348M of Medifast stock for Q4 2014, down 38% quarter-over-quarter.
  • 17 funds opened new Medifast positions in Q4 2014 and 16 closed out, a net change of +1 holder.
  • The largest Medifast buyer in Q4 2014 was Millennium Management, an estimated $4.15M added.
  • The largest Medifast seller in Q4 2014 was Americafirst Capital Management, an estimated $221M sold.

Based on aggregated 13F filings for Q4 2014.